Synaptogenesis comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2026-07-06. Numbers and descriptions here follow the published literature rather than marketing material.
Human data for dihexa remain absent from peer-reviewed clinical literature. As a result, questions about absorption, distribution, metabolism, excretion, and long-term safety are unresolved. Discussions often appear in nootropic forums, where anecdotal reports cannot substitute for controlled trials. Researchers have called for more rigorous pharmacokinetic and toxicological studies before any clinical evaluation. Until such data exist, dihexa is best described as an investigational research compound rather than a proven intervention.
The proposed mechanism for dihexa centers on hepatocyte growth factor, or HGF, and its receptor c-Met. HGF signaling is involved in cell growth, survival, and synapse formation. Dihexa has been described as an HGF mimetic or modulator in preclinical literature. Whether it binds c-Met directly, increases HGF availability, or acts through another route remains uncertain. This mechanistic uncertainty is a recurring theme in reviews of the compound, and no single molecular model has been confirmed across independent laboratories.
Research on dihexa has primarily used rodent models and cultured cells. Common endpoints include dendritic spine density, synaptic protein expression, and performance on maze or avoidance tasks. Some studies report improvements in cognitive measures after scopolamine-induced deficits or in aged animals. These findings are interesting but come from a small body of work, and independent laboratories have not consistently replicated all reported effects. Larger, preregistered studies would help clarify which results are robust.
Early laboratory work focused on its effects on synaptic connectivity and neuronal signaling. In cell and animal models, dihexa has been reported to promote the formation of new synapses, a process called synaptogenesis. These findings have generated interest in cognitive research, but the evidence base remains mostly preclinical. Human clinical trials with clear safety and efficacy endpoints are limited or absent in the public literature. Whether these effects translate to humans is an open question.
The proposed mechanism involves interaction with the hepatocyte growth factor (HGF) system and its receptor, c-Met. Dihexa is described in some studies as an HGF mimetic, meaning it may mimic or enhance HGF-mediated signaling. Activation of c-Met can influence cell growth, survival, and cytoskeletal remodeling, pathways that intersect with synaptic plasticity. However, the precise binding targets and downstream events for dihexa are not fully established, and alternative mechanisms have been suggested.
| Property | Value | Notes |
|---|---|---|
| Primary proposed target | HGF/c-Met signaling | Direct binding not confirmed |
| Research models | Rodent and cell studies | Preclinical only |
| Human clinical data | None published | Safety and efficacy unknown |
| Regulatory status | Unapproved research chemical | Status varies by country |
| Typical research purity | 95% or higher by HPLC | Depends on supplier and batch |
Dihexa is not approved as a medicine in major regulatory jurisdictions. It is commonly sold as a research chemical for laboratory use, though such products may not be standardized or independently verified. Scientific literature on dihexa includes in vitro assays, rodent studies, and reviews that discuss its proposed mechanism. The distinction between peer-reviewed findings and commercial promotion is important when evaluating available information. Open questions include its precise binding interactions, pharmacokinetics, and whether animal results translate to human biology.
Dihexa is a synthetic peptide derived from angiotensin IV, a naturally occurring fragment of the renin-angiotensin system. Researchers modified the angiotensin IV structure to improve metabolic stability and central nervous system activity. It is frequently described as a hepatocyte growth factor mimetic because it can activate the c-Met receptor pathway in experimental systems. Its development reflects interest in small peptides that influence synaptic plasticity and cognitive processes. Most information comes from preclinical studies rather than controlled human trials.
Development of dihexa followed from studies on angiotensin IV analogs and their effects on learning and memory. Researchers sought compounds with improved metabolic stability and brain penetration compared with natural peptides. In preclinical reports, dihexa was associated with changes in synaptic connectivity and performance on spatial tasks. These findings generated interest in its potential as a cognitive research tool. The work remains largely preclinical, and independent replication has been limited.
Regulatory and commercial contexts differ from clinical medicine. Dihexa is not approved as a drug by major agencies, and no published human trials establish its safety or efficacy. It is often sold as a research chemical labeled for laboratory use only. Suppliers may provide certificates of analysis, but purity and identity depend on the specific batch. Legal status varies by country and may treat such compounds as unapproved substances for human consumption.
==== Prostacyclin ==== Prostacyclin (PGI2) is released by endothelium and activates platelet Gs protein-linked receptors. This, in turn, activates adenylyl cyclase, which synthesizes cAMP. cAMP inhibits platelet activation by decreasing cytosolic levels of calcium and, by doing so, inhibits the release of granules that would lead to activation of additional platelets and the coagulation cascade.
==== Psychedelics ==== The Zendo Project conducted by the Multidisciplinary Association for Psychedelic Studies uses principles from psychedelic therapy to provide safe places and emotional support for people having difficult experiences on psychedelic drugs at select festivals such as Burning Man, Boom Festival, and Lightning in a Bottle without medical or law enforcement intervention.
Shaw's 2014 short film SMILF, which she wrote, directed and starred in opposite Thomas Middleditch, won the 2015 Short Film Jury Award for U.S. Fiction at Sundance. In 2015, SMILF was picked up by Showtime as a half-hour comedy television show with Shaw as showrunner, writing, directing, starring in, and producing the series. The first season, which was shot on location in South Boston as well as Los Angeles, received generally positive reviews, with her portrayal of single mother Bridgette Bird notable for its realism, insight, and biting humor. "Frankie Shaw, it [SMILF] marks the arrival of an important and original voice." SMILF co-stars Connie Britton and Rosie O'Donnell, and tackles subjects like eating disorders and sexual abuse. Shaw said that the show was a way to discuss and portray the role of women on screen. In November 2017, Showtime renewed SMILF for a second season. In December 2018, it was reported that Shaw and the series had been accused of workplace misconduct. In March 2019, the series was cancelled after two seasons. In 2016, Shaw returned to the Sundance Film Festival with another short film she wrote and directed, a dark comedy titled Too Legit, which stars Zoë Kravitz, Teresa Palmer, Nate Corddry and Clark Gregg. Too Legit is inspired by a satire of Congressman Todd Akin's controversial 2012 remarks about rape and pregnancy: "It seems to be, first of all, from what I understand from doctors, [rape resulting in pregnancy is] really rare.
== Published works == Code 7: Cracking the Code for an Epic Life. Candy Wrapper. 2017. ISBN 978-1-940556-01-7. Johnson contributed a chapter to the book Architects of Intelligence: The Truth About AI from the People Building It (2018) by the American futurist Martin Ford. The Proto Project: A Sci-Fi Adventure of the Mind. Candy Wrapper. 2019. ISBN 978-1-940556-07-9. Don't Die. Blueprint. 2023. ISBN 978-1-940556-16-1. We the People. Zero. 2023. ISBN 978-1-940556-20-8.
Sources: en.wikipedia.org
== Structure-activity relationship == The structure-activity relationship (SAR) of gliflozins is not fully understood. The most commonly used gliflozins are dapagliflozin, empagliflozin, and canagliflozin. The differences in the structures are relatively small. The general structure includes a glucose sugar with an aromatic group in the β-position at the anomeric carbon. In addition to the glucose sugar moiety and the β-isomeric aryl substituent, the aryl group is composed of a diarylmethylene structure. The synthesis of gliflozins involves three general steps. The first one is the construction of the aryl substituent, the next one is the introduction of the aryl moiety onto the sugar or glucosylation of the aryl substituent, and the last one is the deprotection and modification of the arylated anomeric center of the sugar. Phlorizin was the first type of gliflozin, and it was non-selective against SGLT2/SGLT1. It is a natural O-aryl glycoside composed of a d-glucose and an aromatic ketone. However phlorizin is very unstable, it is rapidly degraded by glucosidases in the small intestines, so it can not be used as an orally administrered medication to treat diabetes. Structural modifications have been made to overcome this instability problem. The most efficient way was to conjugate the aryl moiety with the glucose moiety since C-glucosides are more stable in the small intestines than O-glucoside derivatives (C-C bond instead of C-O-C bond).
== Mechanism == EAAT1 functions in vivo as a homotrimer. EAAT1 mediates the transport of glutamic and aspartic acid with the cotransport of three Na+ and one H+ cations and counter transport of one K+ cation. This co-transport coupling (or symport) allows the transport of glutamate into cells against a concentration gradient.
A proteome is the entire set of proteins that is, or can be, expressed by a genome, cell, tissue, or organism at a certain time. It is the set of expressed proteins in a given type of cell or organism, at a given time, under defined conditions. Proteomics is the study of the proteome.
From amphibians onward, bone management is biodynamic, with bone functioning as internal calcium reservoir under the control of osteoclasts via the combined action of parathyroid hormone and 1α,25-dihydroxyvitamin D3.
In the 1980s, while the number of arrests for all crimes had risen by 28%, the number of arrests for drug offenses rose 126%. In 1994, the New England Journal of Medicine reported that the war on drugs resulted in the incarceration of one million Americans each year. In 2008, The Washington Post reported that of 1.5 million Americans arrested each year for drug offenses, half a million would be incarcerated, and one in five black Americans would spend time behind bars due to drug laws. In 2019, the FBI estimated about 1.5 million drug arrests nationally, 32.1% for cannabis and 31% for "other dangerous nonnarcotic drugs". Federal and state policies also impose collateral consequences on those convicted of drug offenses, separate from fines and prison time, that are not applicable to other types of crime. To comply with a federal law known as the Solomon–Lautenberg amendment, a number of states require a six-months driver's license suspension for anyone convicted of a drug offense. Other examples of collateral consequences for drug offenses, or for felony offenses in general, include loss of professional license, loss of ability to legally purchase a firearm under Federal law, loss of eligibility for food stamps, loss of eligibility for Federal Student Aid, loss of eligibility to live in public housing, loss of ability to vote, and deportation, a total of over 460 benefits at risk at the federal level alone. The US provides for the deportation of non-citizens convicted of drug offenses.
Sources: en.wikipedia.org
==== Monazite identification and mapping ==== Monazite grains are identified by a backscattered electron imaging survey or/and electron microprobe analysis (EMPA) by mapping the concentration of distinctive Ce in monazite. The two images are usually superimposed to reflect sample texture and monazite locations at the same time.
The TAAR1 full agonist RO5166017 and the high-efficacy TAAR1 partial agonist RO5256390, as well as the antipsychotic olanzapine, produced similar effects in these paradigms. Relatedly, RO5263397 produced a pattern of brain activity in rodents similar to that of antipsychotics. In addition, RO5263397 potently suppresses hyperlocomotion in dopamine transporter (DAT) knockout mice. The preceding findings suggest that TAAR1 agonists like RO5263397 have antipsychotic-like properties. In contrast to classical antipsychotics however, RO5263397 did not show extrapyramidal-like symptoms like catalepsy in mice, and instead partially prevented haloperidol-induced catalepsy, suggesting the potential for an improved tolerability profile. RO5263397 has been shown to reduce behavioral sensitization induced by cocaine in mice. Similarly, it reduces the expression but not development of conditioned place preference (CPP) by cocaine in mice. Analogously to cocaine, RO5263397 dose-dependently attenuates behavioral sensitization to methamphetamine, reduces self-administration of methamphetamine, and blocks reinstatement of methamphetamine-seeking behaviors in rodents. It also attenuates methamphetamine-induced impulsivity in rodents. In general, the drug has been found to suppress methamphetamine-, cocaine, and nicotine-induced stimulant-like and reinforcing effects in animals in vivo. Analogous findings have been made for morphine and ethanol. RO5263397 has similar effects compared to TAAR1 full agonists like RO5256390 in vivo in terms of psychostimulant modulation.
Vaxess Technologies, Inc. is a company started by a team of four graduate students from Harvard developing a suite of vaccines on the MIMIX sustained dermal delivery platform that combines high temperature stability, improved efficacy, and simplified delivery to improve global vaccine access.
=== Genetic labeling === Fluorescence in situ hybridization (FISH), is an example of a genetic labeling technique that utilizes probes that are specific for chromosomal sites along the length of a chromosome, also known as chromosome painting. Multiple fluorescent dyes that each have a distinct excitation and emission wavelength are bound to a probe which is then hybridized to chromosomes. A fluorescence microscope can detect the dyes present and send it to a computer that can reveal the karyotype of a cell. This technique allows abnormalities such as deletions and duplications to be revealed.
Sources: en.wikipedia.org
Dihexa has been proposed to act through HGF and c-Met signaling. This pathway is linked to synapse formation and cellular growth. Direct binding and the precise molecular step remain uncertain.
No published human clinical trials are available for dihexa. Its safety and effectiveness in people are therefore unknown. Most available evidence comes from animal and cell studies.
Preclinical studies often measure dendritic spine density and synaptic protein levels. Behavioral tests include maze learning and avoidance tasks. These endpoints are indirect and do not establish clinical benefit.
Dihexa is a synthetic peptide analog of angiotensin IV, often described as an HGF mimetic in research literature. It is studied for effects on synaptic connectivity in laboratory models. It is not an approved medication.